CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 194 enrolled
Drug / intervention
stereotactic radiosurgery +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01372774
NCT01372774Phase 3Completed

A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Alliance for Clinical Trials in Oncology·interventional·Posted Jun 14, 2011·Updated Sep 16, 2022

In Brief

A Phase 3 clinical trial evaluating stereotactic radiosurgery and whole-brain radiation therapy for Cognitive/Functional Effects and 4 related conditions. Completed, enrolled 194 participants across 37 sites.

Detailed Summary

RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether stereotactic radiosurgery is more effective than whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery. PURPOSE: This randomized phase III trial studies how well stereotactic radiosurgery works compared to whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 14, 2011
Enrollment StartJul 1, 2011
Primary CompletionAug 1, 2016
Study CompletionDec 15, 2019
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 15.0 years ago

Interventions

stereotactic radiosurgeryradiation

Undergo RT

whole-brain radiation therapyradiation

Undergo radiotherapy (RT)